795306-68-2

Upstream product

• 163222-33-1 ezetemibe 
• 53008-65-4 methyl 2,3,4-tri-O-benzyl-D-glucopyranoside 
• 795306-66-0 (3R,4S)-3-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-3-(4-fluoro-phenyl)-propyl]-1-(4-fluoro-phenyl)-4-[4-((2R,3R,4S,5R,6S)-3,4,5-tris-benzyloxy-6-methoxy-tetrahydro-pyran-2-ylmethoxy)-phenyl]-azetidin-2-one 
• 795306-55-7 Acetic acid 4-[(2S,3R)-3-[(S)-3-(tert-butyl-dimethyl-silanyloxy)-3-(4-fluoro-phenyl)-propyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenyl ester 
• 795306-57-9 3′-(S)-4-(S)-3-(R)-[3′-t-butyldimethylsilyloxy-3′-(4-fluorophenyl)propyl]-4-(4-hydroxyphenyl)-1-(4-fluorophenyl)azetidin-2-one 
• 795306-53-5 Acetic acid 4-{(2S,3R)-1-(4-fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenyl ester 

Relevant academic research and scientific papers

Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption

We have utilized our recently developed in vitro assay to address two key questions in the design of small-molecule cholesterol absorption inhibitors using ezetimibe, the only drug yet approved for the inhibition of cholesterol absorption in the small int

An in vitro assay for evaluation of small-molecule inhibitors of cholesterol absorption

Giving cholesterol the brush off: An intestinal brush border membrane vesicle assay has been devised for the convenient in vitro testing of small molecules for inhibition of cholesterol absorption. The assay was used to identify new nonhydrolyzable glycosides as potent cholesterol-absorption inhibitors and an oxazolidinone as an effective replacement of the β-lactam scaffold of ezetimibe (1).